There are 2867 resources available
1037P - Taxol-ramucirumab-pembrolizumab (TRP) for immuno-resistant/refractory NSCLC
Presenter: Jiaxin Niu
Session: Poster session 14
1038P - Nanosomal docetaxel lipid suspension (NDLS) monotherapy is effective and well-tolerated in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
Presenter: Chetan Deshmukh
Session: Poster session 14
1039P - Efficacy and safety of surufatinib (HMPL-012) as a third-line or further treatment for advanced non-small cell lung cancer (NSCLC)
Presenter: Yanfang Zheng
Session: Poster session 14
1040P - Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data
Presenter: Magdalena Knetki-Wroblewska
Session: Poster session 14
1041P - Efficacy and safety of chemotherapy after progression on immunotherapy: Results of a multicenter retrospective observational trial
Presenter: Andrea Camerini
Session: Poster session 14
1042P - Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin first-line therapy for advanced non-small cell lung cancer
Presenter: Hongxiang Huang
Session: Poster session 14
1043P - Clinical predictors of benefit from pembrolizumab (pembro) or pembro-chemotherapy (CHT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 14
1044P - Taxanes plus immunotherapy might be a potential option for HER2-altered NSCLC beyond first-line progression: A retrospective real-world study
Presenter: Yaning Yang
Session: Poster session 14
1045P - Comprehensive genomic profiling to guide immunotherapy in lung cancer
Presenter: Joris Van De Haar
Session: Poster session 14
1046P - Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)
Presenter: Jonathan Riess
Session: Poster session 14